FDAnews Drug Daily Bulletin

GVAX IMPROVES SURVIVAL IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER

May 25, 2006
A A

Researchers have reported that the investigative immunotherapy agent GVAX improves predicted survival time with little toxicity in patients with metastatic hormone-refractory prostate cancer (HRPC). These results from two phase II trials were presented at the 2006 annual meeting of the American Urological Association
CancerConsultants.com